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CHAPTER 1 
INTRODUCTION 
1.1 Thyroid hormone 
Thyroid hormone (TH) is essential for a number of physiological processes, protein 
synthesis, neuronal and bone growth, and metabolism in all tissues (Groeneweg et al., 2017). 
Lack of TH in childhood causes the syndrome of cretinism characterized by neurodevelopment 
delay, hearing impairment and stunted growth (Halpern et al., 1991). In adult, hypothyroidism is 
known as myxedema, with impairments in speech, movement, consciousness and intellect 
(Galton, 2005; Osterweil et al., 1992). TH production and secretion by the thyroid gland is 
tightly regulated in hypothalamus and pituitary gland, which secretes thyrotropin releasing 
hormone (TRH) and thyroid stimulating hormone (TSH), respectively, through the 
hypothalamus-pituitary-thyroid (HPT)-axis (Brent, 2012; Mondal et al., 2016). In humans, 
almost 80% of TH secreted by thyroid gland is prohormone thyroxine (T4), while the rest is the 
active form triiodothyronine (T3) (Maia et al., 2005). In order to become biologically active, T4 
must be peripherally transformed into T3 since it is the only form that binds the thyroid hormone 
receptor (TR) (Astapova and Hollenberg, 2013). This process is modulated by deiodinase, 
selenocysteine-containing enzymes, named iodothyronine deiodinase type 1 (Dio1), type 2 
(Dio2) and type 3 (Dio3), which are capable to remove an iodine atom from iodothyronines in 
the inner or outer ring of a TH isoforms (Bianco et al., 2002). Deiodination of T4 outer and inner 
ring initiates the formation of T3 and reverse T3 (rT3), respectively (Fig 1: van der Spek et al., 
2017). T3 can be inactivated by outer ring deiodination, resulting in the generation of 3,3’-
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diiodothyronine (3,3’-T2) (Fig 1: van der Spek et al., 2017). THs are distributed systemically and 
transported into cells by various TH transporters such as monocarboxylate transporters 8 
(MCT8) and MCT10 expressed in various tissues in the whole body, which are responsible for 
both the influx and efflux of TH (Hagenbuch, 2007). In addition, the organic anion transporting 
polypeptide 1C1 (OATP1C1) is predominantly expressed in the brain which aids T4 uptake into 
astrocytes (Mayerl et al., 2014). After transport into cells, the active metabolite T3 binds the 
nuclear TRs, TRα and TRβ to modulate the gene expression via co-activator and co-repressor 
proteins (Yen, 2001). Therefore, intracellular TH action is dependent on both T3 availability and 
its receptors (Ahmed et al., 2010). 
 
 
Figure 1: Deiodination of thyroid hormone isoforms (modified from van der Spek et al., 
2017). 
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1.2 TH and brain 
Normal physiological function and homeostasis in our body need neural and endocrine 
system orchestration. TH plays a pivotal role in neural development such as neural cell migration 
and differentiation, synaptogenesis, myelination and homeostasis. Besides, TH is a critical 
modulator of brain metabolism and one of important factors for enzymes syntheses required for 
neurotransmitters (Porterfield and Hendrich, 1993; Bernal and Nunez, 1995). The brain is highly 
susceptible to TH and its interaction is in a tightly controlled fashion. Neurons are among the 
classical target cells of TH action. TH levels in the brain tissue are strongly dependent on the 
local production of T3 where only a few amount of T3 being derived directly from the 
circulation (Sandler et al., 2004).  
THs enter the brain directly via blood-brain-barrier (BBB) and from the choroid plexus-
cerebrospinal fluid (CSF) taken through TH transporters MCT8 and OATP1C1 (Fig 2: Schroeder 
and Privalsky, 2014). Majority of BBB TH transporters display greater affinities for T4 transport 
(Fig 2: Schroeder and Privalsky, 2014; Heuer, 2007; Chatonnet et al., 2011). Thus, uptake of T4 
is rate-limiting for TH reaction in the brain. 
In the brain, the local T3 production is tightly regulated by the actions of deiodinases, 
transporters and TRs (Bianco and Larsen, 2005). Dio2 is mostly expressed in astrocytes and 
tanycytes while Dio3 is mainly resides in neurons (Bernal, 2007). Following T4 influx to the 
brain, T4 is taken up into astrocytes and the Dio2 can in turn convert it locally to T3 (Fig 2: 
Schroeder and Privalsky, 2014). The astrocytes-generated T3 can enter neuronal cells via MCT8, 
resulting in activation of TRs (Fig 2: Schroeder and Privalsky, 2014).  In adult rats, both T4 and 
T3 reach the brain from blood, but it was estimated that around 80% of the T3 bound to the 
nuclear receptors was produced locally by Dio2 activity (Crantz et al., 1982). As an additional 
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control of neuronal T3 concentration, Dio3 degrades T3 to the inactive metabolite 3,3’-
diiodothyronine (3,3’-T2). Therefore, deiodination is an important step in the activation and 
inactivation of THs (Ahmed et al., 2008). 
 
Figure 2: Entry of TH into brain via the blood-brain-barrier (modified from Schroeder and 
Privalsky, 2014) 
 
1.3 Hypothyroidism and brain 
Many mental disorders such as mood instability, anxiety, cognition and memory impairments 
are associated with thyroid dysfunction in humans and experimental animals (Baldini et al., 
1997; Dugbartey, 1998; Demet et al., 2002; van Boxtel et al., 2004; Fernandaz-Lamo et el., 
2009; Dias et al., 2012; Joffe et al., 2013). Hypothyroidism is also known to be one of the risk 
factors for dementia in Alzheimer’s disease (AD) (Breteler et al., 1991; Ganguli et al., 1996; van 
Osch et al., 2004). In addition, the hypothyroidism induces pseudodementia and progressive non-
degenerative cognitive deficits identified by sluggish in thinking (Dugbartey, 1998). Therefore, 
T4 therapy ameliorates spatial memory and learning in aged mice via increased hippocampal 
ACh levels (Fu et al., 2014). Likewise, levothyroxine administration in hypothyroidism patients 
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significantly increased verbal memory retrieval (Miller et al., 2005). Most clinical psychomotor 
dysfunctions by hypothyroidism are alleviated by hormone replacement therapy. Hippocampal 
morphological plasticity which is critical for memory acquisition is affected by hypothyroidism 
(Madeira et al., 1992). Importantly, T4 replacement therapy reinstates impaired long term 
potentiation (LTP) in hippocampal CA1 region by restoration of Ca2+/calmodulin-dependent 
protein kinase II (CaMKII) and reduced neurogranin level in hypothyroid-induced rats (Alzoubi 
et al., 2005). On the other hand, intraperitoneal administration of L-thyroxine (L-T4) improves 
cognitive dysfunctions and memory in amyloid beta peptide (Aβ)-infused mice (Fu et al., 2010). 
Additionally, anxiety-like behavior shown in adult onset hypothyroidism male mice was rescued 
by TH supplementations (Buras et al., 2014). In this context, homeostasis of THs are essential 
for coordinating neural development and plasticity in the central nervous system (Osterweil et 
al., 1992; Bauer et al., 1998; Altshuler et al., 2001). 
 
1.4 Methimazole 
 Hyperthyroidism is characterized by excessive TH production. Methimazole (MMI) is 
widely used to antagonize hyperthyroidism and manage Graves’ disease, an autoimmune 
condition promoting hyperthyroidism (Cano-Europa et al., 2011; Wu et al., 2013). 
Biochemically, MMI inhibits iodine incorporation into the TH precursor, thyroglobulin, and thus 
interferes with conversion of T4 to T3 (Cooper, 1984; Amara et al., 2012; Parisa and Fahimeh, 
2015). Patients are usually administered MMI prior to undergoing thyroid surgery or radioactive 
iodine (RAI) therapy in order to maintain normal TH metabolism (Sadaf and Riyaz, 2015). 
However, several reports indicate that chronic MMI treatment causes hypothyroidism due to 
improper monitoring of drug dosage (Page et al., 1996; Cakic-Milosevic et al., 2004). In fact, 
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Kallner et al. (1996) reported that most Graves’ disease patients chronically treated with MMI 
(40 mg/day) exhibit hypothyroidism within 12 weeks. 
Large bodies of evidence connect MMI and brain functions disruption. Chronic MMI 
administration increased mRNA level of serotonin receptors, 5-HT1A, 5-HT2A and 5-HT2C 
expression in the raphe nuclei and limbic system thereby leading to depress-like behaviors in rat 
(Tang et al., 2014). Adult-onset hypothyroidism by chronic MMI administration causes reduction 
of hippocampal Na+/K+ ATPase activity with increase in atrophic CA3 hippocampal pyramidal 
cells in rats (Alva-Sanchez et al., 2004; Pacheco-Rosada et al., 2005; Alva-Sanchez et al., 2009). 
Furthermore, the other studies have shown that memory and learning impairments are induced by 
MMI in rats (Hosseini et al., 2010; Dias et al., 2012). However, mechanism underlying cognitive 
impairments by hypothyroidism remains unclear. 
  
Figure 3: Molecular structure of methimazole  
1.5 T-type calcium channel (T-VGCC) and nicotinic acetylcholine receptor (nAChR)  
Calcium acts as an intracellular second messenger and its intracellular elevation activates 
various responses including the activation of enzymes, neurotransmitters and hormones release, 
muscle contraction, cell proliferation, and differentiation (Lechleiter and Clapman, 1992; Perez-
Reyes, 2003). Voltage-gated calcium channels can be classified by electrophysiological criteria 
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into high- and low-voltage-activated channels. Low-voltage-activated channels, T-VGCCs are 
extensively expressed in various types of neurons and have a distinctive voltage dependence, fast 
inactivation and small single-channel conductance. T-VGCCs subtypes have been discovered 
encoded by Cav3.1, Cav3.2 and Cav3.3 which responsible to complexes containing the pore-
forming α1 subunits, α1G, α1H and α1I, respectively (Perez-Reyes, 2003). T-VGCCs are 
activated by small depolarization of the plasma membrane and cause the influx of two positive 
charges with every calcium ion leads to a further depolarization of the membrane, thereby 
triggering burst firing action potential mediated by sodium channels in neurons (Huguenard, 
1996). Indeed, T-VGCC disturbance is associated with many neurological disorders, including 
sleep disorders, absence epilepsy, neuropathic pain, Parkinson’s disease and neuropsychiatric 
disorders (Llinas and Ribary, 2001).  
Acetylcholine (ACh) is one of important neurotransmitters for neuronal plasticity (Huerta 
and Lisman, 1995). nAChRs are divided into either heteromeric (has both α and β subunits) or 
homomeric (has only α subunits) receptors. nAChRs are extensively localized in both pre- and 
postsynapse in the brain (Dani and Bertrand, 2007). The nAChRs participate in modulation of 
neuronal development and synaptic plasticity, and have pivotal role in memory, learning and 
attention (Melancon et al., 2013; Pandya and Yakel, 2013). Nevertheless, neuronal nAChRs 
disruption promotes various neurodegenerative diseases including epilepsy, schizophrenia, 
Parkinson’s disease, AD and autism (Dani and Bertrand, 2007; McKay et al., 2007; Szabo et al., 
2008).   
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1.6 SAK3 
 Previously, our laboratory has developed a novel cognitive enhancer ST101 (ZSET1446: 
spiro [imidazo[1,2-a] pyridine-3,2-indan]-2(3H)-one) which improves memory and cognitive 
deficits by rescuing loss of cholinergic neurons in medial septum (MS) observed in olfactory 
bulbectomized (OBX) mice (Han et al., 2008). Using whole-cell patch clamp technique, we 
found one of targets of ST101 as Cav3.1 T-VGCC (Moriguchi et al., 2012). We also indicate that 
acute administration of 1.0 mg/kg ST101 via intraperitoneal route in mice promotes hippocampal 
ACh release, an effect blocked by T-VGCC antagonist mibefradil (Yamamoto et al., 2013). In 
addition, chronic ST101 administration rescues depress-like behaviors in OBX mice, effects 
suppressed by the non-selective nAChR inhibitor mecamylamine (MEC) (Shioda et al., 2010). 
Other study group reported that chronic ST101 administration improved spatial memory 
dysfunctions in triple-transgenic (3xTg) Alzheimer model mice (Green et al., 2011). In the 
clinical study, combination of ST101 with donepezil, a cholinesterase inhibitor, improves 
memory in AD patients, however, ST101 treatment alone showed negligible benefit for AD 
patients in a phase II clinical trial in the USA (Gautheir et al., 2015). 
 Recently, we established a novel spiroimidazopyridine derivative, SAK3 (ethyl-8’-methyl-
2’,4-dioxo-2-(piperidin-1-yl)-2’H-spiro[cyclopentane-1-2-ene-3 carboxylate], which is more 
effective than ST101 as Cav3.1 and Cav3.3 T-VGCC enhancer (Yabuki et al., 2017a). Acute 
administration with SAK3 but not ST101 significantly promotes ACh release in the hippocampal 
CA1 region and then improves cognitive deficits in OBX mice, an effect blocked by T-VGCC 
inhibitor NNC 55-0396 treatment (Yabuki et al., 2017a). Moreover, chronic SAK3 
administration shows neuroprotective effects against neuronal loss following transient brain 
ischemia in the hippocampal CA1 region through activating nAChR signalling (Yabuki et al., 
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2017b). However, the efficacy of SAK3 on cognitive deficits induced by hypothyroidism is not 
evaluated. 
 
Figure 4: Molecular structure of SAK3  
1.7 Olfactory bulb and cholinergic pathway 
Since cholinergic neurons in medial septum (MS) innervate the olfactory bulb (OB) and 
hippocampus (Mesulam et al., 1983a), OBX leads to retrograde degeneration of cholinergic 
neurons in MS and then concomitant loss of hippocampal cholinergic neurons, suggesting that 
impaired OB injures cholinergic system (Han et al., 2008). Previous study indicated that MMI 
treatment lesions olfactory epithelium (OE) and then leads to detachment of olfactory sensory 
neurons (OSNs) in the OB (Bergman et al., 1999; Blanco-Hernandez et al., 2012). TH deficiency 
also causes significantly reduced levels of choline acetyltransferase (ChAT), a marker of 
cholinergic neurons, in various brain regions (Kojima et al., 1981; Oh et al., 1991; Sawin et al., 
1998). Loss of MS cholinergic neurons is also associated with cognitive deficits seen in 
Alzheimer’s disease (Robinson et al., 2011). Although dysfunction of the MS cholinergic system 
in the latter condition is associated with impaired olfactory function (Esiri and Wilcock, 1984) 
and cholinergic dysfunction may be involved in hypothyroidism-induced cognitive decline, the 
precise cause/effect relationship between MS cholinergic neuron degeneration and OB 
dysfunction remains unclear.   
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1.8 Objectives 
The objectives in the present study are to investigate the mechanism underlying 
hypothyroidism-induced memory deficits and the effect of SAK3 on it as followed. 
a) Evaluation of the effect of chronic SAK3 administration in single MMI injection model. 
b) Evaluation of the effect of acute SAK3 administration in twice MMI injection model. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1 Animals 
Female 12-week-old ddY mice were purchased from Japan SLC (Hamamatsu, Japan). 
Mice were housed under conditions of constant temperature (23 ± 1 oC) and humidity (55 ± 5%) 
with a 12-h light-dark cycle and were fed ad libitum. All experimental animal procedures were 
approved by the Committee on Animal Experiments at Tohoku University, and studies were 
conducted according to committee guidelines. Every effort was made to minimize suffering and 
limit the number of animals used. 
2.2 Experimental design 
 In this study, two mice models were established. In the first model, mice were randomly 
divided into 6 groups; I: control (euthyroid); II:control + SAK3 (1.0 mg/kg/oral); III: MMI 
(hypothyroid); IV, V and VI: MMI (hypothyroid) + SAK3 (0.1, 0.5 and 1.0 mg/kg/oral, 
respectively). Hypothyroidism was induced by a single intraperitoneal (i.p.) injection (75 mg/kg) 
of MMI (Sigma-Aldrich, St-Louis, MO, USA). Control mice were similarly administered normal 
saline. SAK3 was dissolved at various concentrations (0.1, 0.5 and 1 mg/kg) in double-distilled 
water. Twenty four hours after MMI administration, mice were given SAK3 orally once daily for 
10 days. Behavioral tests were started at day 7 after SAK3 administration. 
Meanwhile in the second model, animals were grouping as shown below. Mice were received 
MMI through intraperitoneal (i.p.) injection (75 mg/kg) for 2 weeks (once a week) (Sigma-
Aldrich, St-Louis, MO, USA). Control mice were given normal saline. Four weeks after last 
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MMI administration, mice were assessed by behavioral analyses. Thirty minutes before oral 
SAK3 administration, mice were given either α7 nAChR-selective inhibitor MLA (12 mg/kg, 
i.p.; Sigma-Aldrich, St-Louis, MO, USA) or T-VGCC specific blocker NNC 55-0396 (25 mg/kg, 
i.p.; Sigma-Aldrich, St-Louis, MO, USA). Subsequently, mice were subjected to behavioral 
analyses 1 hour after SAK3 treatment. 
A. Chronic SAK3 administration in single MMI injection model 
Groups:  
1. Control + vehicle 
2. Control + 1.0 mg/kg SAK3 
3. MMI + vehicle 
4. MMI + 0.1 mg/kg SAK3 
5. MMI + 0.5 mg/kg SAK3 
6. MMI + 1.0 mg/kg SAK3 
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B. Acute SAK3 administration in twice MMI injection model 
 
Groups: 
1. Control + vehicle 
2. Control + 1.0 mg/kg SAK3 
3. Control + MLA (12 mg/kg/i.p.) 
4. Control + NNC (25 mg/kg/i.p.) 
5. MMI + vehicle 
6. MMI + 1.0 mg/kg SAK3 
7. MMI + 1.0 mg/kg SAK3 + MLA (12 mg/kg/i.p.) 
8. MMI + 1.0 mg/kg SAK3 + NNC (25 mg/kg/i.p.) 
 
 
2.3 Y- maze task 
Spontaneous alternation behavior in a Y-maze served as a test of spatial reference 
memory as conducted by Yabuki et al (2015). Briefly, mice were placed in an apparatus 
consisting of three identical black Plexiglas arms (50 x 16 x 32 cm). Animals were placed at the 
end of one arm and permitted to move through the maze for an 8-min session, while the sequence 
of arm entries was recorded manually. An alternation was defined as entry into all three arms on 
continuous choices. The maximum number of alternations was defined as the total number of 
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arms entered minus two, whereas the percentage of alternations was calculated as actual 
alternations/maximum alternations x 100. The total number of arms entered was also observed 
throughout the session. 
 
2.4 Novel object recognition (NOR) task 
This task tests the ability of mice to distinguish a familiar from a novel object and was 
conducted as described by Moriguchi et al. (2011). To avoid bias the experimenter scoring 
behavior was blinded to the treatment. Two objects made from the same material were 
positioned in a symmetric position in the center of the chamber for 10 min throughout 
acquisition phases. One hour later, one object was substituted with a novel object, and 
exploratory behavior was observed for 5 min. After every session, objects were cleaned 
thoroughly using 70% ethanol to prevent odor recognition. Exploration of an object was 
characterized by rearing on the object, sniffing it at a distance less than 1 cm or touching it with 
the nose. Successful recognition was represented by preferential exploration of the novel object. 
Spatial novelty discrimination was evaluated by comparing differences in the number of 
exploratory contacts of novel and familiar objects and the total number of contacts with both, 
allowing adjustment for differences in total exploration time contacts. 
 
2.5 Sucrose preference test 
Mice were fasted 24 hours before the test. During the 1-hour test period, mice were 
singly housed and provided 2 bottles of different drinking solution (a 1 % sucrose solution or tap 
water). Water and sucrose intake was assessed by weighing bottles before and after the test 
period. Sucrose preference, which is decreased in mouse models of depression, was calculated as 
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a percentage of consumed sucrose solution relative to the total amount of liquid consumed 
(Strekalova et al., 2004). 
2.6 Tail suspension test 
The test was performed as reported by Steru et al. (1985). Briefly, animals were fastened 
by the tail with adhesive tape for 10 minutes and the amount of time they remained immobile 
was recorded during that period. Mice were judged immobile when they hung passively and 
remained totally motionless.  
 
2.7 Elevated plus maze test 
The maze included of two open and two closed arms (all 25 x 5 cm) attached to a central 
platform. Animals were placed on the central platform (5 x 5 cm) facing a closed arm and 
permitted to freely explore the maze for 10 min. Time spent in open or closed arms, and total 
entries into both open and closed arms were recorded (Nascimento Hackl and Carobrez, 2007). 
 
2.8 Plasma T4 level assessment 
Blood samples were collected in tubes coated with EDTA and spun at 1000 x g for 15 
min within 30 min of collection. T4 levels were determined using an enzyme-linked 
immunosorbent assay (ELISA) kit according to the manufacturer's protocol (Elabscience 
Biotechnology Co., Ltd, Beijing, China). Samples were measured in duplicate. 
 
2.9 Immunohistochemistry 
Immunohistochemistry was performed as described by Shioda et al. (2010). Briefly, mice 
were anesthetized and perfusion-fixed with 4% paraformaldehyde. After removing brain, 50 µm 
16 
 
thick coronal MS sections were cut using a vibratome (Dosaka EM Co. Ltd., Kyoto, Japan). 
Sections were incubated in PBS containing 0.01 % Triton X-100 (30 min) and immersed in 3% 
H2O2 in PBS to block endogenous peroxidase activity. To block non-specific binding, 1% bovine 
serum albumin (BSA) + 0.3% Triton was applied to sections overnight. Sections were then 
incubated 7 days in primary antibody against goat anti-ChAT (1:200, Millipore, Billerica, MA, 
USA) or goat anti-olfactory marker protein (OMP) (1:500;Wako Chemical USA, Richmond, 
VA, USA). Sections were washed in PBS and incubated with biotinylated mice anti-goat IgG 
(1:200; Jackson ImmunoResearch, West Grove, PA, USA). Avidin biotin complex (ABC) 
solution (Vector Laboratories Inc., Burlingame, CA, USA) was incubated for 3 hours and then 
immunohistochemical complexes were visualized by exposure to 3’3’-diaminobenzidine-
tetrahydrochloride (DAB; Sigma-Aldrich) for 10 min. Stained sections were washed in PBS 
before dehydration in increasing concentrations of ethanol. Sections were then rinsed in xylene, 
mounted in Entellan (MERCK, Dannstadt, Germany) and coverslipped. Images were captured by 
bright-field light microscopy (Olympus BX51WI, Tokyo, Japan). ChAT-positive MS neurons 
were counted, and OMP intensity in the OB glomerular layer and glomerulus size were 
quantified using ImageJ software. 
 
2.10 Real time PCR 
Total RNA from MS tissues was isolated using TRI Reagent (Sigma) according to the 
manufacturer’s instructions. In brief, tissues were homogenized in TRI Reagent and mixed 
thoroughly with 23-gauge needle on ice. Subsequently, chloroform was added and the mixture 
was incubated on ice for 15 minutes before centrifuged at 15,000 rpm for 5 min at 40C. The 
supernatant was collected and combined with isopropanol. Then, the samples were spun down at 
15,000 rpm for 20 min at 40C. RNA pellets were washed with 75% ethanol and were eluted in 
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0.1% diethyl-pyrocarbonate (DEPC)-treated deionized water (Sigma) to block RNA degradation. 
cDNAs were synthesized by reverse transcriptase as described by Shioda et al [26]. Real-time 
PCR was performed with iQ CYBR Green Supermix (Bio-Ras Laboratories, Redmond, WA) 
following the manufacturer’s protocol. The primers were: mouse forward ChAT, 5’- 
CCTGTACAAGCTTCTAGCTGTG–3’;reverse ChAT, 5’- GTAGCTAAGCACACCAGATGAG 
– 3’; mouse forward GAPDH, 5’ -TGTGTCCGTCGTGGATCTGA - 3’; and reverse GAPDH, 5’ 
– CACCACCTTCTTGATGTCATCATAC – 3’. 
 
2.11 Statistical analysis 
Statistical analysis was performed using the Sigma Plot (Systat Software, CA, USA). 
Results were interpreted using one-way analysis of variance (ANOVA) followed by multiple 
comparisons between control and other groups using Dunnett’s multiple comparison test. 
Significant differences were determined using Student’s t test for two-group comparisons 
(discrimination index in Fig. 8C, 8D, 11C and 11D). Data were expressed as means ± SEM in 
triplicate. A difference was considered significant at p<0.05. 
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CHAPTER 3 
 
RESULTS 
 
A. Chronic SAK3 administration in single MMI injection model 
 
3.1 Chronic SAK3 administration antagonizes MMI-induced reduction of T4 levels 
First, we evaluated serum T4 levels to confirm hypothyroidism status treated by MMI. 
We observed a significant group effect in all treatment groups on serum T4 level [F (5, 24) = 
24.707, p<0.001]. As expected, mice treated with MMI showed reduced T4 levels (Table 1). By 
contrast, after 1 week of chronic SAK3 administration (at 0.1, 0.5 and 1 mg/kg), decreased T4 
levels in MMI-treated mice were partly but significantly restored (Table 1).  
 
          Groups T4 concentration (ng/ml) 
Control + vehicle 12.00 ± 0.66 
Control + 1 mg/kg SAK3 19.02 ± 2.2 
MMI + vehicle 4.08 ± 0.44 
MMI + 0.1 mg/kg SAK3 8.00 ± 0.37 
MMI + 0.5 mg/kg SAK3 
MMI + 1 mg/kg SAK3 
7.50 ± 0.75 
14.00 ± 0.87 
 
Table 1: MMI-induced decrease in serum T4 levels was rescued by chronic SAK3 
administration. Data are expressed as means ± S.E.M. (*p< 0.05 vs control, **p< 0.01 vs 
control, #p< 0.05 vs MMI, ##p< 0.01 vs MMI). n = 5 per group. 
 
 
** 
# * 
# * 
## 
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3.2 Chronic SAK3 administration restores impaired OB glomerulus structure in MMI-
induced hypothyroid mice 
OMP is exclusively expressed in mature OSNs (Margolis, 1972), its axons converge on 
single OB glomeruli (Touhara et al., 1999). Anatomically, we observed well-organized 
spherically shaped olfactory glomeruli in the OB of control mice. By contrast, convergence of 
OSN axons on glomeruli in OB glomerular layers was severely disrupted in MMI-induced 
hypothyroid mice. We evaluated OMP intensity by densitometry analysis in the glomerular layer 
and observed a significant group effect [F(5, 36) = 4.372, p=0.003]. Impaired axonal 
convergence seen in most glomeruli following MMI treatment was rescued by acute SAK3 
administration (at 0.1, 0.5 and 1 mg/kg: Fig 5A). Chronic SAK3 administration (0.1, 0.5 and 1 
mg/kg, p.o.) significantly antagonized reduced in OMP protein expression seen in MMI-induced 
hypothyroid mice (Fig 5B). We next evaluated a potential SAK3 effect on glomerular size. 
Relevant to this parameter, we observed a significant group effect in all treatment groups [F(5, 
36)= 3.599, p=0.01]. Compared with control mouse, MMI-treated mice showed significantly 
decreased glomerular size, whereas chronic SAK3 administration at 0.5 or 1 mg/kg restored OB 
glomerular size to that seen in control mice (Fig 5C). Taken together, SAK3 antagonized loss of 
OMP intensity and changes in glomerular size induced by MMI. 
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Figure 5: The MMI-induced decrease in OMP expression in OB glomeruli is ameliorated 
by chronic SAK3 administration 
(A) Schematic diagram of OB, MS and hippocampus in the brain (B) Coronal sections of OB 
from indicated control (c), MMI-treated, or MMI-treated and SAK3-treated (0.1, 0.5 and 1 
mg/kg) mice were incubated with OMP antibody. (C) SAK3 treatment significantly restored 
intensity (C) and increased area (D) of OMP expression in the OB glomerular layer. Scale bar, 
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50 µm. Error bars represent S.E.M. (**p< 0.01 vs control, #p < 0.05 and ##p< 0.01 vs MMI). n = 
7 per group. 
3.3 MMI-induced disruption of the cholinergic system is rescued by chronic SAK3 
administration 
Based on previous studies of cholinergic innervations of mouse OB, we hypothesized that 
cholinergic neurons undergo retrograde degeneration in hypothyroid mice. We observed a 
significant group effect in all treatment groups in terms of the number of ChAT-positive cells in 
the MS area [F(5, 36) = 3.635, p = 0.009]. In control MS sections without MMI treatment (Fig 
6A), the number of ChAT-positive cells was comparable in vehicle- and SAK3- (1mg/kg) treated 
groups (Fig 6B). Notably, the number of ChAT-positive cells following MMI treatment 
markedly decreased in vehicle-treated mice, while chronic SAK3 administration rescued the 
number of MS ChAT-positive cells in MMI-treated animals (Fig 6B). Chronic SAK3 
administration at 1 mg/kg completely restored the number of ChAT-positive cells in MMI-
treated mice. Taken together, chronic SAK3 administration to MMI-treated mice restored not 
only glomerular structure but also cholinergic innervations from the septum to glomeruli, a 
pathway severely impaired by MMI treatment. 
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Figure 6: Chronic SAK3 administration rescues the MMI-induced decrease in the number 
of ChAT positive cells in the MS  
(A) Photomicrographs showing anti-ChAT staining in the MS area. (B) ChAT-positive cells 
were counted in the MS in control and MMI-treated mice with or without SAK3 administration 
(0.1, 0.5 and 1 mg/kg). Scale bar, 100 µm. Error bars represent S.E.M. (**p< 0.01 vs control, #p 
<0.05 and ##p< 0.01 vs MMI). n = 7 per group. 
 
3.4  Chronic SAK3 treatment ameliorates MMI-induced memory deficits 
In mice, olfactory bulbectomy promotes retrograde degeneration of MS cholinergic 
neurons and is closely associated with memory deficits (Han et al, 2008). Moreover, cholinergic 
neurons innervate frontal cortex and hippocampus (Semba, 2004). Thus, MMI-induced 
degeneration of MS cholinergic neurons may account for memory deficits seen in mice. To 
address this possibility, we first assessed memory behavior in mice using both Y-maze and novel 
object recognition (NOR) tests. In terms of the Y-maze test, we observed a significant group 
effect on total arm entries [F (5, 90) = 3.061, p = 0.013] and spontaneous alternation behavior 
[F(5, 90) = 16.845, p<0.001]. Chronic administration of SAK3 (at 0.1, 0.5 and 1 mg/kg) 
significantly improved alternation behavior performance (Fig 7A) in MMI-treated mice 
compared with mice that received MMI only, without changing the total arm entries (Fig. 7B). 
As a test of cognitive function, we conducted the NOR test based on the inherent tendency of 
mice to explore a novel object more frequently than a familiar one (Antunes and Biala, 2012). 
We observed no difference in discrimination index using similar objects in all groups during the 
training session (Fig. 7C). Following a 1-hour retention interval between trial and test sessions, 
control mice not treated with MMI but administered vehicle or SAK3 could distinguish novel 
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from similar objects (Fig. 7D), while MMI-treated mice that did not receive SAK3 could not 
(Fig. 7D). Under the same conditions, administration of 1 mg/kg SAK3 to MMI-treated mice 
significantly rescued the discrimination index for a novel object, while SAK3 treatment at 0.1 or 
0.5 mg/kg did not (Fig. 7D). Overall, however, these findings suggest that chronic SAK3 
treatment improves special reference memory and cognition impaired by MMI treatment. 
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Figure 7: Chronic SAK3 administration improves impairment memory related-behaviors 
induced by MMI 
(A) In a Y maze, MMI-treated mice show deceased alternation behaviors relative to vehicle-
treated controls, a phenotype rescued by SAK3 (0.1, 0.5 and 1 mg/kg). (B) In Y maze test, total 
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arm entries are relatively unchanged in control, MMI-treated, and SAK3-treated groups. Error 
bars represent SEM. **p< 0.01 vs. vehicle-treated control mice. ##p< 0.01 vs. vehicle-treated 
MMI mice. (C) In novel object recognition (NOR) test, all groups show no comparable 
performance in trial sessions, while MMI and MMI + 0.1 and 0.5 mg/kg SAK3 groups cannot  
recognize a novel object in the test session. (D) Administration of SAK3 at 1 mg/kg improved 
the discrimination index. Error bars represent SEM. **p< 0.01 vs right group. n = 16 per group. 
 
3.5  MMI-induced hypothyroidism does not affect depression and anxiety behaviors 
To assess other neurobehavioral abnormalities potentially induced by MMI, we employed 
sucrose preference and tail suspension tests to assess depression-like behaviors (Krishnan and 
Nestler, 2011; Overstreet, 2012) and an elevated plus maze test to evaluate anxiety (Pawlak et 
al., 2012). We observed no statistically significant differences in sucrose intake (Fig 8A) in all 
test groups, including MMI, SAK3, and/or control groups [F (5, 30) = 0.536, p = 0.748], 
suggesting that none of these drug treatments induces depression. In the tail suspension test (Fig 
8B), which also measures depression as evidenced by immobility time, we also observed no 
significant group effect among all treatment groups [F (5, 38) = 0.183, p = 0.967]. Finally, in the 
elevated plus maze test, we observed no behaviors indicative of anxiety among groups (Fig 8C) 
(p > 0.05) [F (5, 38) = 0.0834, p = 0.994].  
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Figure 8: MMI-treated mice do not evoke depression and anxiety-related behaviors. 
(A) Sucrose preference test showed no obvious depression behaviors (p > 0.05). (B) In tail 
suspension test, the immobility time (sec) was not difference among all groups, indicating 
absence of depression (p > 0.05). (C) In elevated plus maze, all mice did not display anxiety 
behavior which is determined by times spent in close arm (p > 0.05). Error bars indicate SEM. n 
= 6 – 8 per group. 
B. Acute SAK3 administration in twice MMI injection model 
 
3.6 The acute effect of SAK3 on MMI-induced decreased T4 levels in the serum 
At first, we determined serum T4 levels to confirm hypothyroidism status after MMI 
treatment. Since single injection of MMI-induced hypothyroidism may be transient (Ogawa et 
al., 2014; Xie et al., 2011), we treated twice with MMI (75 mg/kg, i.p.) once a week in order to 
cause continuous hypothyroidism. In 4 weeks after final MMI treatment, a significant group 
0
100
200
300
400
500
600
Ti
m
e
 (
s) close
open
C 
Control Methimazole 
  Veh 1 mg/kg 
SAK3 
     Veh 0.5 mg/kg 
SAK3 
0.1 mg/kg 
SAK3 
1 mg/kg 
SAK3 
30 
 
effect in all groups on serum T4 level [F (2, 15) = 8.225, p = 0.004] was discovered. MMI-
treated mice displayed a significant reduced T4 levels as compared to control (Fig 9), however 
acute SAK3 administration did not affect the T4 levels in MMI-treated mice (Fig 9).  
 
 
 
 
Figure 9: Acute SAK3 administration does not affect MMI-induced reduction of serum T4 
levels. 
Data are expressed as mean ± S.E.M. (**p< 0.01 vs control). n = 6 per group. 
 
3.7  Acute SAK3 administration improves memory deficits in MMI-induced mice 
Next, we evaluated the acute effect of SAK3 on memory deficits in MMI-treated mice. A 
significant group effect on spontaneous alternation behavior [F(7, 40) = 4.798, p<0.001] (Fig 
10A) were observed in Y-maze test results after 4 weeks of MMI induction without changes in 
the total arm entries [F (7, 40) = 1.120, p = 0.370] (Fig 10B). MMI-treated mice showed the 
significant reduction of alternation behaviors compared to control animals (p < 0.001 vs. control) 
(Fig.10A). Acute SAK3 (1.0 mg/kg, p.o.) administration significantly improved impaired spatial 
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memory in MMI-treated mice (p < 0.001 vs. MMI group) (Fig. 10A). In novel object recognition 
(NOR) test, there were no significant differences in the discrimination index during trial session 
in all animal groups (Fig. 10C). Acute SAK3 (1.0 mg/kg, p.o.) administration also rescued the 
ability to discriminate novel object for familiar one in MMI-treated mice (Fig 10D). Notably, 
SAK3 effect on memory deficits in Y-maze and NOR tests seen in MMI-treated mice were 
significantly antagonized by MLA (12 mg/kg, i.p.) or NNC 55-0396 (25 mg/kg,i.p.) treatment 
(alternation in the Y-maze: MLA: p = 0.011 vs. MMI + SAK3 group, NNC 55-0396: p = 0.05 vs. 
MMI + SAK3 group).MLA (12 mg/kg, i.p.) or NNC 55-0396 (25 mg/kg,i.p.) alone treatment did 
not affect memory-related behaviors in control mice (Fig. 10). These results suggest that SAK3 
enhances cognitive performances in MMI-treated mice via activating α7 nAChR and T-VGCC 
acutely.  
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Figure 10: Acute SAK3 administration antagonizes MMI-induced cognitive deficits 
through activating T-type calcium channels and nAChR.  
(A) Alternation behavior in Y-maze task in MMI-induced mice decreased as compared with 
control mice without changes in the number of arm entries (B) meanwhile 1 mg/kg SAK3 
administration improved the impairment. Pre-treatment with MLA and NNC 55-0396 blocked 
the neuroprotective effect of SAK3. Error bars represent S.E.M. *p< 0.05 vs. vehicle-treated 
control mice, **p< 0.01 vs. vehicle-treated control mice; ##p< 0.01 vs. vehicle-treated MMI mice; 
ꝉ p< 0.05 vs. SAK-treated MMI mice, ꝉ ꝉp< 0.01 vs. SAK-treated MMI mice (C) No differences 
were noticed in trial session for all groups in novel object recognition task (D) A decline in 
discrimination index was observed in MMI induced mice and was improved by 1 mg/kg SAK3 
administration, an effect prevented by MLA and NNC 55-0396 administration. Error bars 
represent SEM. *p< 0.01 vs right group,**p< 0.01 vs right group. n = 6 per group. 
 
3.8  MMI-induced hypothyroidism does not alter depression and anxiety behaviors 
We further asked whether MMI-treated mice displayed depression like behavior as 
shown in previous study (Dias et al., 2012). In the attempt to determine depression behavior 
possibly promoted by MMI, we performed sucrose preference task and tail suspension test 
(Krishnan et al., 2011; Overstreet, 2012). There was no statistically significant differences in 
sucrose intake (Fig 11A) in all test groups [F (7, 40) = 1.09, p = 0.388], suggesting that none of 
these drug treatments appear to cause stress-induced anhedonia. Anhedonia is defined as lack of 
pleasure in response to a formerly rewarding stimuli and it is a sign for depression (American 
Psychiatric Association, 2013). In the tail suspension test (Fig 11B), we also observed no 
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significant group effect among all treatment groups [F (7, 40) = 0.574, p = 0.773], as exhibited 
by immobility time. 
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Figure 11: Twice MMI treatment do not cause depress- and anxiety-like behaviors in mice. 
All groups do not display depression behaviors as been assessed by (A) sucrose preference test 
and (B) tail suspension test (p > 0.05). Error bars indicate SEM. n = 6 per group. 
3.9  Acute SAK3 administration is unable to rescue impaired OSN expression in the OB 
treated by MMI 
OMP is widely accepted as a molecular marker of mature OSN (Margolis, 1972), where 
OMP immunostaining is important to determine regeneration of OSNs and their projections to 
the OB (Lee et al., 2011). As MMI treatment decreases OMP levels and then injures systematic 
spherical structures in the OB (Xie et al., 2011; Uranagase et al., 2012; Noreen et al., 2017), we 
next performed a morphometric analysis on glomeruli size in MMI-treated mice followed by 
acute SAK3 administration. A significant group effect was observed in glomeruli size [F(7, 40) = 
3.642, p= 0.004]. As shown in Fig 12B, the size of olfactory glomeruli was relatively small in 
MMI-treated mice compared to control, owing to part exposure to an olfactory toxicant, MMI 
whose metabolites induce cell death of OSN (Brittebo, 1995). Neither SAK3 administration nor 
pre-incubation with MLA and NNC55-0396 was able to restore decreased in glomeruli size 
under the same condition. 
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Figure 12: The acute effect of SAK3 on MMI-induced disruption of OSNs in the OB. 
(A) Samples from OB were incubated with OMP antibody. In the glomeruli, there was a 
perturbation in the OSNs convergence induced by MMI whereby SAK3 administration unable to 
restore the impairment (B) Quantitative analyses of glomerular area of OB. Scale bar, 100 µm. 
Error bars represent S.E.M. (*p< 0.05 vs control,**p< 0.01 vs control). n = 6 per group. C = 
control, M = methimazole, MS = methimazole + 1.0 mg/kg SAK3, MM = methimazole + 1.0 
mg/kg SAK3 + MLA, MN = methimazole + 1.0 mg/kg SAK3 + NNC. 
 
3.10  Acute SAK3 administration does not restore MMI-induced loss of the cholinergic 
neurons in the medial septum   
Finally, we confirmed the acute effect of SAK3 on reduction of ChAT positive cells in 
the MS in MMI-treated mice (Noreen et al., 2017). A significant group effect was observed in 
number of ChAT positive cells [F(7, 40) = 2.981, p= 0.013] and mRNA expression levels [F(7, 
40) = 9.214, p< 0.001]. We found a striking decrease in both ChAT immunoreactivities and 
mRNA levels in MMI mice compared to that of control mice (IHC: p < 0.01; mRNA: p < 0.01; 
Fig 13B, C). Administration of acute SAK3 could not significantly reinstate the declining 
number in ChAT positive cells in MMI-treated mice with or without MLA or NNC 55-0396 
treatment. Those results suggest that SAK3 improves memory deficits observed in MMI-treated 
mice.  
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Figure 13: The acute effect of SAK3 on MMI-induced reduction of ChAT 
immunoreactivities and mRNA levels in the MS. 
(A) Distribution of positively labelled cholinergic neurons by ChAT-immunochemistry in the 
MS area. Scale bar, 100 µm. (B) Quantifications of ChAT positive cells and (C) ChAT mRNA 
expression which the positive cells and expression were significantly decreased in MMI group. 
Acute administration of acetylcholine enhancer, SAK3 could not significantly rescue the 
cholinergic neurons generated by MMI. Error bars represent S.E.M. (**p<0.01 vs control). n = 6 
per group. C = control, M = methimazole, MS = methimazole + 1.0 mg/kg SAK3, MM = 
methimazole + 1.0 mg/kg SAK3 + MLA, MN = methimazole + 1.0 mg/kg SAK3 + NNC. 
 
 
 
 
 
0
20
40
60
80
100
120
140
C
h
A
T 
m
R
N
A
 e
xp
re
si
io
n
(%
 o
f 
co
n
tr
o
l)
C 
Control Methimazole 
 Veh    NNC 1 mg/kg 
SAK3 
MLA +            
1 mg/kg 
SAK3 
  Veh 1 mg/kg 
SAK3 
   MLA NNC +           
1 mg/kg 
SAK3 
 ** 
  ** 
 **  ** 
41 
 
 
CHAPTER 4 
 
DISCUSSION 
 
 Adult onset of hypothyroidism is associated with impaired spatial memory performance and 
cognitive function (Tong et al., 2007; Artis et al., 2012). However, mechanisms underlying such 
memory impairments remain unclear. Here, we address the possible mechanism of cognitive 
impairment and propose SAK3 as a potential therapeutic. Our study reveals the following. 1) 
Perturbation of OSN maturation by a single and twice MMI treatment is accompanied by a 
decrease in the number of MS cholinergic neurons. 2) Degeneration of cholinergic neurons likely 
causes memory and cognitive deficits seen in single and twice MMI treatment mice. 3) Chronic 
SAK3 treatment of single MMI-treated mice rescues MS cholinergic neurons and improves 
deficits in spatial reference memory and cognition. 4) Twice injection of MMI could induce 
consecutive hypothyroidism at least 4 weeks; and 5) α7 nAChR antagonist and T-VGCC 
inhibitor abolished the effect of acute SAK3 in MMI-treated mice. 
 
 In the mammalian olfactory system, OSNs are located in the OE lining the nasal cavity. 
There, as they mature, OSNs regenerate continuously, and their axons enter the OB and branch 
in glomeruli (Cummings and Belluscio, 2008). Mature OMP-positive OSNs finally synapse with 
bulb cells (Uraganase et al., 2012). MMI is commonly used to manage hyperthyroidism but is 
associated loss of smell in patients (Genter et al., 1995). Such toxicity is thought to affect the OE 
and is related to tissue-specific and cytochrome P450 (CYP)-dependent bioactivation of reactive 
intermediates metabolites (Eriksson and Brittebo, 1991), such as sulfenic and sulfinic acids, 
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which bind covalently to proteins of Bowman’s glands in the lamina propria of the olfactory 
mucosa (Bergman and Brittebo, 1999; Bergstrom et al., 2003). The appearance of reactive 
intermediate metabolites following MMI administration may underlie the drug's toxic effects 
(Kedderis and Rickert, 1985; Henderson et al., 2004) and induce apoptosis of OE OSNs 
(Bergman and Brittebo, 1999; Sakamoto et al., 2007), potentially causing OE detachment and 
damage to the lamina propria (Brittebo, 1995). Although OSNs generally regenerate rapidly, 
some have reported that moderate OE damage can persist for as long as 3 months after MMI 
administration (Bergman et al., 2002). 
 
 Previous reports reveal that hypothyroidism can arise by improper clinical drug monitoring 
following chronic MMI treatment (Page et al., 1996; Cakic-Milosevic et al., 2004). For example, 
Kallner et al (1996) reported that most Graves’ disease patients treated with MMI (40 mg/day) 
become hypothyroid after 12 weeks of administration. Various strategies have been used to 
promote hypothyroidism in animals, including surgical ablation of thyroid gland (Alzoubi et al., 
2005), radio-thyroidectomy using isotopes (Usenko et al., 1999) and through pharmacological 
approach using antithyroid drugs such as MMI and propylthiouracil (PTU) (Cano-Europa et al., 
2011; Dias et al., 2012). Administration of antithyroid drugs reversibly inhibits TH production. 
Hypothyroidism induction by administration of MMI in the drinking water displayed a few 
drawbacks in terms of its hepatic first-pass metabolism and took longer time to induce thyroid 
hormone deficiency in animals as compared to intraperitoneal route (Dias et al., 2012; Sayafee et 
al., 2016). Here, we demonstrated that single and twice injection of MMI (75 mg/kg, i.p.) 
induces hypothyroidism in mice and twice MMI injection was able to maintain continuous 
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hypothyroidism 4 weeks after final MMI injection. Therefore, our model may be useful and 
convenient as hypothyroidism-induced cognitive impairment model mice. 
 Mackay-Sim and Beard (1987) previously showed that normal T4 levels are essential for 
proper neuronal differentiation and maturation of OSNs in adult mice. TH functions in synthesis 
and assembly of ribosomal and microtubular proteins, namely, tubulin, in rats (Fellous et al., 
1979).  Lack of T3 may decrease synthesis of microtubular proteins and thus alter OSN axonal 
growth and maturation (Bernal and Nunez, 1995). A prominent sign of hypothyroidism in rats is 
lack of OSN maturation marked by reduced OMP staining of olfactory axon bundles within the 
OE, a pattern indicative or decreased numbers of sensory afferents (Paternostro and Meisami, 
1996; Margolis, 1972). Likewise, in hypothyroid rats, the surface area of the olfactory receptor 
sheet and the number of OSNs in OE decreased by nearly half after treatment with another 
antithyriod drug, n-propylthiouracil (PTU) (Paternostro and Meisami,1989 and 1991). 
 
 The OSN signalling is regulated by cholinergic and GABAergic neurons located in the 
nucleus of the horizontal limb of the diagonal band in rats (D’Souza and Vijayaraghavan, 2014; 
Zaborszky et al., 1986). TH deficiency interferes with CNS cholinergic neuron development, 
causing decreased ACh and ChAT levels in rat brain (Kalaria and Prince, 1985; Kojima et al., 
1981). In rats, cholinergic neurons MS and nucleus basalis magnocellularis (NBM) are the 
primary source of cholinergic innervations of the hippocampus and cerebral cortex (Mesulam, 
1996). The importance of cholinergic neurons to learning, memory and attention is well 
documented in mice and rats (Baxter and Chiba, 1999; Everitt and Robbins, 1997). Our data 
support the idea that impaired projection of cholinergic neurons from the MS to OB underlies 
destruction of glomerular structures in the latter. ChAT levels in cholinergic neurons in other 
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brain areas innervated by the MS are also reduced (Oh et al., 1991). In olfactory bulbectomized 
(OBX) mice, a decline in the number of cholinergic neurons accompanies decreased ChAT 
expression (Han et al., 2008; Hozumi et al., 2003; Nakajima et al., 2007). Several groups have 
reported that cholinergic neuron degeneration seen following OBX is due to retrograde 
degeneration of MS neurons (Zaborszky et al., 1986; Han et al., 2008; D’Souza and 
Vijayaraghayan, 2014). Furthermore, OBX increases Aβ levels in brain (Aleksandrova et al., 
2004) and triggers degeneration of septo-hippocampal cholinergic neurons in mice (Hozumi et 
al., 2003; Yamada et al., 2011). Therefore, retrograde degeneration of MS neurons following 
olfactory injuries by MMI treatment may be one of explanations of cognitive deficits by MMI-
induced hypothyroidism. Further studies are necessary in the future to define the other critical 
events to induce cognitive deficits. 
 
 In the present study for single MMI injection mice model, we report a neuroprotective effect 
of chronic SAK3 administration on MMI-induced impairment of ChAT-positive cells in MS 
(Fig. 6). We previously showed that the prototype T-VGCC enhancer ST101 has neuroprotective 
and neuroregenerative effects in OBX mice, thereby improving memory-related behaviors 
(Shioda et al., 2010). Whereas acute administration of SAK3 but not ST101 promotes 
hippocampal ACh release (Yabuki et al., 2017a), ACh released from septum cholinergic neurons 
may protect those neurons through stimulating nAChRs (Yamamoto and Fukunaga, 2013). 
Previous work has revealed that stimulation of nAChRs enhances cell survival by the 
phosphatidylinositol 3-kinase (PI3K)-Akt pathway (Akaike et al., 2010). We also confirmed that 
ST101 rescues mouse septum cholinergic neurons by activating Akt pathways in OBX mice 
(Yamamoto and Fukunaga, 2013). Likewise, SAK3 antagonizes neuronal loss following 
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transient brain ischemia through stimulating nAChR-Akt signaling in the hippocampus CA1 
region (Yabuki et al., 2017b). From our present findings, axonal convergence in the OB 
glomerular structures was markedly disrupted following MMI-induced injury based on 
expression of OMP, which is exclusively expressed in mature OSN (Margolis, 1972). However, 
in the present study for single MMI injection mice model, the mechanism underlying restored 
olfactory glomerular structure by chronic SAK3 remains unknown. In mice, cholinergic fibers 
from the MS innervate those structures, and ACh released nerve terminals may maintain 
glomerular structure by rescuing OSNs and thus contribute to amelioration of memory and 
learning in MMI-treated mice. Further studies are required to define the mechanism of 
neuroprotective effect of SAK3 on loss of OSNs and septal cholinergic neurons from MMI-
induced olfactory damage. 
 
We previously documented that acute SAK3 administration orally promotes hippocampal 
ACh release and then improves memory deficits in OBX mice through enhancing T-VGCCs 
(Yabuki et al., 2017a). All three types of T-VGCCs (Cav3.1, Cav3.2 and Cav3.3 isoforms) are 
predominantly found in the brain (Talley et al., 1999) and function in maintenance of synaptic 
plasticity. Blocking T-VGCCs by Ni2+(50 μM) disturbs long-term depression in rat 
somatosensory cortex (Nevian and Sakman, 2006) and low-threshold calcium spikes in newly 
generated granule cells in adult rat hippocampus (Schmidt et al., 2004). Moreover, elevated      
T-VGCC activities in the mediodorsal thalamic nucleus are associated with impaired fear 
extinction learning seen in phospholipase Cβ4 knockout mice (Lee et al., 2011). Therefore,       
T-VGCCs may play an important role for memory and cognition. On the other hand, the 
activation of nAChRs is also critical for memory formation and synaptic plasticity (Kawai et al., 
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2007). The α7nAChR agonist BMS-902483 enhances novel object recognition memory in wild-
type naïve mice (Pieschl et al., 2017). In addition, α7nAChR knockout mice show cognitive 
impairments which were corroborated as declines in sustained attention and olfactory working 
memory span (Young et al., 2007a). Acute SAK3 administration significantly improved impaired 
spatial memory and cognition observed in twice MMI-treated mice, an effect inhibited by MLA 
or NNC 55-0396. Additionally, SAK3 also improves memory-related behavior in bilateral 
common carotid arteries occlusion mice via activation of nAChR (Yabuki et al., 2017b). 
Therefore, SAK3 may rescue impaired memory in MMI treated mice by both T-VGCC 
activation and α7nAChR enhancement. 
 
 It has been reported that adult hypothyroidism elevates the risk of neuropsychiatric and 
cognitive impairment, outcomes associated with anomalous neural growth and differentiation, 
excitability and plasticity in hippocampus (Cortes et al., 2012; Gilbert and Paczkowski, 2003; 
Martinez-Sanchez et al., 2014). Although mechanisms underlying cognitive impairment by 
hypothyroidism are complex, our results suggested one of the mechanisms via reduction of 
cholinergic functions. In conclusion, we assess a mouse model of cognitive impairment 
following a single and twice treatment of MMI, which causes severe hypothyroidism. 
Additionally, reduction of cholinergic neurons in MS may be a primary cause of memory 
impairments in MMI-treated mice. Our results indicate that chronic and acute SAK3 
administration can improve impairments of memory and learning by single and twice injection of 
MMI-induced hypothyroidism, respectively. Treatment with SAK3 rescued not only injured 
septal cholinergic neurons but also OSNs by MMI-induced hypothyroidism in mouse brain. 
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Taken together, SAK3 may be attractive candidate for the therapy of hypothyroidism-related 
cognitive impairment. 
 
Figure 14 : SAK3 protects injured neurons by MMI. MMI induce damage in the OB, thus 
triggers retrograde degeneration of cholinergic neurons in the MS. This event can alter 
synaptic function in the hippocampus and induce memory and learning dysfunction. SAK3 
administration rescues OB damage and MS cholinergic neurons degeneration, and finally 
antagonizes memory and learning impairments. 
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